News Column

Idera Pharmaceuticals Inks Agreement with Abbott

May 14, 2014

Idera Pharmaceuticals, Inc., a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced that it has entered into an agreement with Abbott, a global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera's clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.

According to a release, under the agreement, Abbott will develop a test utilizing polymerase chain reaction technology to identify the presence of the MYD88 L265P oncogenic mutation in tumor biopsy samples with high sensitivity and specificity. This mutation, which can be identified in approximately 90 percent of patients with Waldenstrom's macroglobulinemia and approximately 30 percent of patients with the ABC sub-type of diffuse large B-cell lymphoma, plays a key role in activating the Toll-like receptor pathways targeted by Idera's lead drug candidate, IMO-8400.

"Research by Idera and by independent investigators has established TLR antagonism as a potentially promising and novel therapeutic approach for patients with B-cell malignancies harboring the MYD88 L265P mutation," said Lou Brenner, M.D., Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals. "This companion diagnostic will be an important tool for the clinical community in evaluating whether their patients are potential candidates for IMO-8400 therapy for the treatment of these genetically defined forms of B-cell lymphoma. We are excited about the opportunity to partner with Abbott, a leader in companion diagnostics, as part of Idera's mutation- targeted development program for IMO-8400 in B-cell lymphomas."

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Beauty Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters